Sp36
TARGETING THE EPIGENOME IN PANCREATIC CANCER
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
The epigenome is the heritable portion of the genome that is mediated by chemical modification of DNA (methylation) or nuclear proteins (histones, transcription factors) without changing the DNA sequence. This session will focus on what defines the epigenome, technologies that allow us to track the epigenome and how novel cancer therapies are developed that target regulators of the epigenome.
The epigenome is the heritable portion of the genome that is mediated by chemical modification of DNA (methylation) or nuclear proteins (histones, transcription factors) without changing the DNA sequence. This session will focus on what defines the epigenome, technologies that allow us to track the epigenome and how novel cancer therapies are developed that target regulators of the epigenome.
Presenter
Tracks
Related Products
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
